Antonio Piñero-Madrona

Dr. Antonio Piñero-Madrona

Department of General Surgery, Breast Unit Surgery, University Hospital "Virgen de la Arrixaca", BioMedical Research Institute of Murcia (IMIB-Arrixaca), University of Murcia, E-30120 Murcia, Spain
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2015 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
APAntonio Piñero-Madrona
Antonio Piñero-Madrona
JTJ A Torró-Richart
J A Torró-Richart
JLJ M De León-Carrillo
J M De León-Carrillo
GCG De Castro-Parga
G De Castro-Parga
JNJ Navarro-Cecilia
J Navarro-Cecilia
G(Grupo De Estudios Senológicos De La Sociedad Española De Patologia Mamaria (Sespm)
Grupo De Estudios Senológicos De La Sociedad Española De Patologia Mamaria (Sespm)

19 February 2019 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
APAntonio Piñero-Madrona
Antonio Piñero-Madrona
GRG. Ruiz-Merino
G. Ruiz-Merino
PFP. Cerezuela Fuentes
P. Cerezuela Fuentes
EME. Martínez-Barba
E. Martínez-Barba
JRJose Neptuno Rodriguez-Lopez
Jose Neptuno Rodriguez-Lopez
JHJuan Cabezas Herrera
Juan Cabezas Herrera

23 June 2016 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
APAntonio Piñero-Madrona
Antonio Piñero-Madrona
GCGregorio Castellanos-Escrig
Gregorio Castellanos-Escrig
JAJesús Abrisqueta-Carrión
Jesús Abrisqueta-Carrión
MCManuel Canteras-Jordana
Manuel Canteras-Jordana

1 January 2015 in Cirugía Española
Verified
Journal Article
Closed access
APAntonio Piñero-Madrona
Antonio Piñero-Madrona
MEMaría J. Escudero-Barea
María J. Escudero-Barea
FFFrancisco Fernández-Robayna
Francisco Fernández-Robayna
JAJosé A. Alberro-Adúriz
José A. Alberro-Adúriz
AGAntonio García-Fernández
Antonio García-Fernández
CSConstantí Serra-Genís
Constantí Serra-Genís

1 December 2014 in The Breast
Verified
Journal Article
Closed access
APAntonio Piñero-Madrona
Antonio Piñero-Madrona
GRGuadalupe Ruiz-Merino
Guadalupe Ruiz-Merino
LBLaia Bernet
Laia Bernet
BMBegoña Miguel-Martínez
Begoña Miguel-Martínez
FVFrancisco Vicente-García
Francisco Vicente-García
JGJulia Giménez-Climent
Julia Giménez-Climent

6 April 2020 in Breast Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
APAntonio Piñero-Madrona
Antonio Piñero-Madrona
FRFrancisco Ripoll-Orts
Francisco Ripoll-Orts
JSJosé I. Sánchez-Méndez
José I. Sánchez-Méndez
ACAsunción Chaves-Benito
Asunción Chaves-Benito
MBMaximiliano Rodrigo Gómez-De la Bárcena
Maximiliano Rodrigo Gómez-De la Bárcena
VPVicente Peg-Cámara
Vicente Peg-Cámara
Background: A prognostic model based on the results of molecular analysis of sentinel lymph nodes (SLN) is needed to replace the information that staging the entire axilla provided. The aim of the study is to conduct an external validation of a previously developed model for the prediction of 5-year DFS in a group of breast cancer patients that had undergone SLN biopsy assessed by the One Step Nucleic Acid Amplification (OSNA) method. Methods: We collected retrospective data of 889 patients with breast cancer, who had not received systemic treatment before surgery, and who underwent SLN biopsy and evaluation of all SLN by OSNA. The discrimination ability of the model was assessed by the area under the ROC curve (AUC ROC), and its calibration by comparing 5-years DFS Kaplan–Meier estimates in quartile groups of model predicted probabilities (MPP). Results: The AUC ROC ranged from 0.78 (at 2 years) to 0.73 (at 5 years) in the training set, and from 0.78 to 0.71, respectively, in the validation set. The MPP allowed to distinguish four groups of patients with heterogeneous DFS (log-rank test p < 0.0001). In the highest risk group, the HR were 6.04 [95% CI 2.70, 13.48] in the training set and 4.79 [2.310, 9.93] in the validation set. Conclusions: The model for the prediction of 5-year DFS was successfully validated using the most stringent form of validation, in centers different from those involved in the development of the model. The external validation of the model confirms its utility for the prediction of 5-year DFS and the usefulness of the TTL value as a prognostic variable.